Pharmacological management of low milk supply with domperidone: separating fact from fiction
Authors: Luke E Grzeskowiak and Lisa H Amir
Published online: 6 April 2015
To the Editor: After publication of our peer-reviewed perspective article on the safe and effective use of domperidone in the management of low milk supply,1 we are disappointed to have been informed that the Australian medicines handbook (AMH) has removed lactation stimulation as a recognised off-label indication for domperidone (as well as metoclopramide). It appears that this change could be a kneejerk response to recent regulatory warnings, despite these being highlighted as not being of relevance to most breastfeeding women.1,2 These changes carry with them the significant potential to create confusion among prescribers and the public.
We would like to re-emphasise the points we have made previously that further restrictions regarding the use and availability of domperidone do not appear to be warranted; they risk subjecting women to additional emotional trauma and are not in the interests of the immediate and long-term health of breastfeeding women and their babies.1,2 There is absolutely no evidence that domperidone places breastfeeding mothers at increased risk of severe cardiac events, whereas, in contrast, there is evidence of the significant benefits to be gained from the use of domperidone in supporting breastfeeding. Domperidone has been used widely in clinical practice for women experiencing low milk supply,3 with no reports of significant adverse effects.
We also re-emphasise our previous practice points regarding the importance of adequately screening women for factors that may place them at increased risk of cardiac arrhythmia, should this be of concern.
It is clear that domperidone is not a magic bullet for adequate milk production in breastfeeding women. Non-pharmacological management options are the mainstay of treatment, with medications only to be considered as a last resort, and always in addition to these management strategies.4 There is no easy fix when it comes to supporting women who are struggling with low milk supply, but when used appropriately, domperidone can be a very safe and effective treatment option.
Competing interests
No relevant disclosures.
Acknowledgements
Luke Grzeskowiak acknowledges salary support from a National Health and Medical Research Council Australian Public Health Fellowship (ID1070421).
References
- Grzeskowiak LE, Amir LH. Pharmacological management of low milk supply with domperidone: separating fact from fiction. Med J Aust 2014; 201: 257-258. _ENREF_1
- Grzeskowiak L. Use of domperidone to increase breast milk supply: are women really dying to breastfeed? J Hum Lact 2014; 30: 498-499. _ENREF_2
- Grzeskowiak LE, Lim SW, Thomas AE, et al. Audit of domperidone use as a galactogogue at an Australian tertiary teaching hospital. J Hum Lact 2013; 29: 32-37. _ENREF_3
- State Government of Victoria, Department of Education and Early Childhood Development. Promoting breastfeeding. Victorian Breastfeeding Guidelines. Melbourne: Department of Education and Early Childhood Development, 2014. http://www.education.vic.gov.au/Documents/childhood/professionals/health/brestfeedguidelines14.pdf (accessed Nov 2014).
Getting on the Same Page: Why Australia Needs a National Maternity Early Warning System (MEWS) Chart
Briony A. Cutts, Lucy Bowyer, Nisha Khot, Sandra Lowe, Stefan C. Kane
Four Urgent Actions for the Rights to Culturally Safe Breastfeeding for Aboriginal and Torres Strait Islander Mothers and Babies to Breastfeed in Neonatal Intensive Care Environments
Jessica Bennett, Jamie Bryant, Kade Booth, Michelle Kennedy
Interpreting Australian Stillbirth Rate Trends: Implications for Surveillance and Continuous Quality Improvement
Aleena M. Wojcieszek, Kirstine Sketcher-Baker, Christine Andrews, Michael Coory, Imogen Kettle, Melissa Malivoire, David Ellwood, Vicki Flenady
The clinical presentation, investigation, and management of women diagnosed with endometriosis in Australian general practices, 2011–2021: an open cohort study
Danielle Mazza, Kailash Thapaliya, Sharinne B Crawford, Alissia Hui, Maryam Moradi, Luke E Grzeskowiak
The early implementation phase of the Omega‐3 Test‐and‐Treat Program for reducing the risk of preterm birth, South Australia, 2021–22: an implementation evaluation study
Karen P Best, Celine Northcott, Lucy A Simmonds, Philippa Middleton, Lisa N Yelland, Vanessa Moffa, Khoa Lam, Penelope Coates, Cornelia Späth, Carol WK Siu, Karen Glover, Rhiannon Smith, Robert Gibson, Maria Makrides
Concurrent use of hormonal long‐acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013–2021
Aaron E Boyce, Tony Caccetta, Jo‐Ann See, Rosemary L Nixon AM